A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by stimulating the mother’s immune system to produce protective antibodies, which are then transferred to the developing baby through the placenta. This mother-derived protection provides newborns with immediate protection from the moment of birth, exactly when they are highly susceptible to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85% protection when vaccinated four weeks before birth
- Maternal antibodies transferred through the placenta protect newborns from day one
- Coverage achievable with two-week gap before premature birth
- Vaccination during third trimester still offers meaningful protection for infants
Compelling evidence from current research
The effectiveness of the pregnancy RSV vaccine has been demonstrated through a extensive research programme undertaken in England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This accounts for approximately nine out of ten of all births during that six-month timeframe, providing strong and reliable information of the vaccine’s real-world impact. The study’s results have been validated by the UK Health Security Agency as showing robust protection for newborns during their earliest and most vulnerable period. The breadth of this investigation gives healthcare professionals and parents-to-be with trust in the vaccine’s established performance across different groups and contexts.
The results reveal a compelling picture of the vaccine’s protective power. More than 4,500 babies were hospitalised with RSV during the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This marked difference underscores the vaccine’s essential role in protecting against serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a major public health success, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.
Study design and parameters
The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection levels and hospital admissions. The sizeable sample and thorough nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than individual cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for optimal protection, as well as to determine whether protection continued to be effective with reduced timeperiods. The methodology measured practical outcomes rather than laboratory-based settings, providing real-world data of how the vaccine functions when delivered across different clinical contexts and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the risks
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.
The infection triggers deep inflammation in the lungs and airways, making it extremely challenging for affected infants to feed and breathe adequately. Parents frequently observe their babies struggling visibly, their chests heaving as they try to pull adequate oxygen into their compromised lungs. Whilst the majority of babies improve through clinical support, a limited though important number die from RSV-related complications yearly, making prevention through vaccination a critical public health priority for protecting the youngest and most at-risk people in our communities.
- RSV triggers inflammation in lungs, resulting in severe breathing difficulties in babies
- Nearly 50% of newborns contract the virus in their first few months of life
- Symptoms span from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK infants need serious hospital treatment for RSV annually
- Small numbers of infants succumb to RSV complications annually in the UK
Uptake rates and professional guidance
Since the RSV vaccine programme commenced in 2024, health officials have highlighted the importance of pregnant women receiving their jab at the optimal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing matters greatly for guaranteeing newborns benefit from the maximum immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery delivers approximately 85% protection, experts encourage women to get their vaccine as early as possible from 28 weeks of pregnancy forward to maximise the antibodies transferred to their babies through the placenta.
The messaging from health authorities remains clear: pregnant women ought to prioritise vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has reassured expectant mothers that protection remains still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those delivering slightly early. This flexible approach acknowledges the realities of pregnancy and childbirth whilst maintaining strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional variations in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others remain focused to increase awareness and access to the jab. These geographical variations reflect variations in healthcare infrastructure, engagement approaches, and community involvement initiatives, though the overall statistics demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts rolling out varied communication campaigns to connect with pregnant women
- Geographic variations in immunisation take-up across England require targeted improvement
- Regional health providers modifying schemes to meet local requirements and situations
Real-world impact and parent viewpoints
The vaccine’s outstanding effectiveness delivers real advantages for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the introduction of this safeguarding intervention, the 80% reduction in admissions represents thousands of infants protected against serious illness. Parents no more face the distressing scenario of watching their newborns labour to breathe or difficulty feeding, symptoms that define critical RSV illness. The vaccine has markedly changed the terrain of neonatal lung health, giving expectant mothers a active means to protect their most vulnerable children during those critical early months.
For families like that of Malachi, whose serious RSV infection caused severe brain damage, the vaccine’s availability carries profound emotional significance. His mother’s support of the jab highlights the profound consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story strikes a chord with parents now given protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to expectant mothers in their third trimester, converting what was once an predictable seasonal threat into a manageable health risk.